Compare the best Biotech stocks, get the most updated comparison by key indicators and discover each stock’s price target as well as recommendations by top Wall Street experts.

Compare up to 7 stocks

Clear

GILD AMGN VRTX BIIB ILMN

Comparison Results

GILDGilead Sciences

$69.07

0.54 (0.79%)

$78.58

(13.77% Upside)

86.63B

285.50

-4.42%

10Buy

6Hold

0Sell

Moderate Buy

AMGNAmgen

$252.38

1 (0.4%)

$244.00

(-3.32% Downside)

145.01B

20.80

10.85%

8Buy

9Hold

2Sell

Moderate Buy

VRTXVertex Pharmaceuticals

$216.35

-0.74 (-0.34%)

$273.08

(26.22% Upside)

56.01B

20.70

-23.59%

11Buy

4Hold

0Sell

Moderate Buy

BIIBBiogen

$280.40

0.19 (0.07%)

$312.69

(11.52% Upside)

42.22B

14.50

-11.30%

9Buy

9Hold

2Sell

Moderate Buy

ILMNIllumina

$379.48

-1.55 (-0.41%)

$426.00

(12.26% Upside)

55.40B

89.00

10.72%

4Buy

4Hold

2Sell

Hold

Performance Comparison

Compare the performance , dividend, and cannabis stocks. Go to the Stock Comparison tool to compare more stocks on key indicators.

Biotech Stocks Latest News

Biogen Collaborates With Capsigen To Develop New Gene Therapies

Biogen (BIIB) has entered into a research collaboration with Capsigen Inc. to develop novel adeno-associated virus (AAV) capsids....

Kailas SalunkheMay 11, 2021

BIIB

Amgen’s 1Q Results Disappoint; Shares Drop 8%

Amgen’s (AMGN) shares fell around 8% in early trading on Wednesday as the biopharmaceutical company reported disappointing results....

Shrilekha PetheApr 28, 2021

AMGN

Gilead To Scale Up Remdesivir Availablity In India

Biopharmaceutical company Gilead Sciences is expanding the availability of its COVID-19 treatment Remdesivir in India amid the country’s...

Kailas SalunkheApr 27, 2021

GILD

Amgen Reports Results From Otezla’s Phase 3 Trial For Treatment Of Plaque Psoriasis

Amgen presented results from the Phase 3 ADVANCE trial of Otezla in patients with plaque psoriasis at the...

Kailas SalunkheApr 26, 2021

AMGN

Biogen Revenue Drops 24% In 1Q; Shares Plunge 4%

Biogen’s share price fell 4% on Thursday after the company reported first-quarter financial results and increased its full-year...

Neha GuptaApr 23, 2021

BIIB

Amgen Completes The Acquisition Of Five Prime Therapeutics

Amgen has completed the acquisition of the clinical-stage biotechnology company Five Prime Therapeutics. Amgen had previously announced a...

Neha GuptaApr 20, 2021

AMGN FPRX AMGEN

Amgen’s Bemarituzumab Receives Breakthrough Therapy Designation

Amgen’s investigational treatment bemarituzumab has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration based on...

Kailas SalunkheApr 20, 2021

AMGN

Biogen’s TECFIDERA Approved In China For Treating Multiple Sclerosis

Biogen Inc’s TECFIDERA has received approval from the National Medical Products Administration (NMPA) in China for treating relapsing...

Kailas SalunkheApr 16, 2021

BIIB

Gilead’s Bladder Cancer Drug Trodelvy Gets FDA Nod

Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) has been granted accelerated approval by the US Food and Drug Administration (FDA)...

Shrilekha PetheApr 14, 2021

GILD

Amgen Snaps Up Rodeo Therapeutics For $721M

Amgen Inc. has agreed to acquire private biopharmaceutical company Rodeo Therapeutics Corporation for a total consideration of $721...

Kailas SalunkheMar 31, 2021

AMGN AMGEN

Read the latest stock news and analysis from the TipRanks news team.

See All News >

Recent Analysts Ratings of Biotech Stocks

AMGNAmgen Inc

Premium

Buy

Premium

Assigned

2021-05-16

VRTXVertex Pharmaceuticals Inc.

Premium

Buy

Premium

Reiterated

2021-05-12

GILDGilead Sciences

Premium

Buy

Premium

Reiterated

2021-05-09

BIIBBiogen Inc.

Premium

Hold

Premium

Reiterated

2021-05-07

ILMNIllumina

Premium

Buy

Premium

Reiterated

2021-04-28

GILDGilead Sciences

Premium

Buy

Premium

Reiterated

2021-05-07

GILDGilead Sciences

Premium

Buy

Premium

Reiterated

2021-05-03

GILDGilead Sciences

Premium

Buy

Premium

Reiterated

2021-05-03

AMGNAmgen Inc

Premium

Hold

Premium

Reiterated

2021-05-03

VRTXVertex Pharmaceuticals Inc.

Premium

Hold

Premium

Assigned

2021-04-30

All Ratings >

Most Recent Earnings of Biotech Stocks

GILDGilead Sciences

Apr 29, 2021

2021 (Q1)

2.08/1.37

1.221

12.20% (+0.15)

AMGNAmgen

Apr 27, 2021

2021 (Q1)

4.05/2.83

3.072

-7.78% (-0.24)

VRTXVertex Pharmaceuticals

Apr 29, 2021

2021 (Q1)

2.70/2.49

2.287

9.05% (+0.21)

BIIBBiogen

Apr 22, 2021

2021 (Q1)

4.98/2.69

8.083

-66.68% (-5.39)

ILMNIllumina

Apr 27, 2021

2021 (Q1)

1.39/1.00

1.169

-14.46% (-0.17)

Biotech Stocks - FAQ

Which Biotech stocks have a "Strong Buy" analyst rating?

These Biotech stocks currently have a "Strong Buy" analyst rating consensus:

None of the selected stocks have a “Strong Buy” analyst rating consensus.

Are Biotech stocks overpriced?

Gilead Sciences's stock price is currently $69.07, and its average 12-month price target is $78.58.

Amgen's stock price is currently $252.38, and its average 12-month price target is $244.00.

Vertex Pharmaceuticals's stock price is currently $216.35, and its average 12-month price target is $273.08.

Biogen's stock price is currently $280.40, and its average 12-month price target is $312.69.

Illumina's stock price is currently $379.48, and its average 12-month price target is $426.00.

Which Biotech stocks pay dividends?

Gilead Sciences currently pays a dividend of $0.71 which represents an annual dividend yield of 4.14%. Gilead Sciences's next Ex-dividend date is June 14, 2021 and its next payout date is June 29, 2021.

Amgen does not currently pay dividends.

Vertex Pharmaceuticals does not currently pay dividends.

Biogen does not currently pay dividends.

Illumina does not currently pay dividends.